@article {7921,
	title = {Primary treatment of Waldenstr{\"o}m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide},
	journal = {Journal of Clinical Oncology},
	volume = {25},
	year = {2007},
	note = {Cited By :104Export Date: 21 February 2017},
	month = {2007},
	pages = {3344 - 3349},
	abstract = {Purpose: Alkylating agents and the anti-CD20 monoclonal antibody rituximab are among appropriate choices for the primary treatment of symptomatic patients with Waldenstr{\"o}m macroglobulinemia (WM), and they induce at least a partial response in 30\% to 50\% of patients. To improve these results, we designed a phase II study that included previously untreated symptomatic patients with WM who received a combination of dexamethasone, rituximab, and cyclophosphamide (DRC). Patients and Methods: Seventy-two patients were treated with dexamethasone 20 mg intravenously followed by rituximab 375 mg/m2 intravenously on day 1 and cyclophosphamide 100 mg/m2 orally bid on days 1 to 5 (total dose, 1,000 mg/m2). This regimen was repeated every 21 days for 6 months. Patients{\textquoteright} median age was 69 years and many had features of advanced disease such as anemia (57\%), hypoalbuminemia (40\%), and elevated serum beta2-microglobulin (43\%). Results: On an intent-to-treat basis, 83\% of patients (95\% CI, 73\% to 91 \%) achieved a response, including 7\% complete, 67\% partial, and 9\% minor responses. The median time to response was 4.1 months. The 2-year progression-free survival rate for all patients was 67\%; for patients who responded to DRC, it was 80\%. The 2-year disease-specific survival rate was 90\%. Treatment with DRC was well tolerated, with 9\% of patients experiencing grade 3 or 4 neutropenia and approximately 20\% of patients experiencing some form of toxicity related to rituximab. Conclusion: Our large, multicenter trial showed that the non-stem-cell toxic DRC regimen is an active, well-tolerated treatment for symptomatic patients with WM. {\textcopyright} 2007 by American Society of Clinical Oncology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548229503\&doi=10.1200\%2fJCO.2007.10.9926\&partnerID=40\&md5=4ef9022f58a64e47287808d992d2c180},
	author = {Dimopoulos, M.A. and Anagnostopoulos, A. and Kyrtsonis, M.-C. and Zervas, K. and Tsatalas, C. and Kokkinis, G. and Repoussis, P. and Symeonidis, A. and Delimpasi, S. and Katodritou, E. and Vervessou, E. and Michali, E. and Pouli, A. and Gika, D. and Vassou, A. and Terpos, E. and Anagnostopoulos, N. and Economopoulos, T. and Pangalis, G}
}
